Tags

Type your tag names separated by a space and hit enter

The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease.
Therap Adv Gastroenterol. 2017 Feb; 10(2):243-251.TA

Abstract

Dexlansoprazole modified-release (MR) is the R-enantiomer of lansoprazole and is currently the only proton-pump inhibitor (PPI) with a novel dual delayed release (DDR) formulation. Overall, dexlansoprazole MR demonstrates a similar safety and side-effect profile as lansoprazole. Dexlansoprazole MR has been shown to be highly efficacious in healing erosive esophagitis, maintaining healed esophageal mucosa in patients with erosive esophagitis and controlling symptoms of patients with nonerosive reflux disease (NERD). Recent studies have also demonstrated that dexlansoprazole MR is highly effective in improving nocturnal heartburn, gastroesophageal reflux disease (GERD) related sleep disturbances and bothersome regurgitation. Dexlansoprazole MR is well tolerated and can be taken without regard to food.

Authors+Show Affiliations

Professor of Medicine, Case Western Reserve University, Director, Division of Gastroenterology and Hepatology, Head, Esophageal and Swallowing Center, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109, USA.The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center and Case Western Reserve University, Cleveland, OH, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28203282

Citation

Fass, Ronnie, and Rosita Frazier. "The Role of Dexlansoprazole Modified-release in the Management of Gastroesophageal Reflux Disease." Therapeutic Advances in Gastroenterology, vol. 10, no. 2, 2017, pp. 243-251.
Fass R, Frazier R. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017;10(2):243-251.
Fass, R., & Frazier, R. (2017). The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therapeutic Advances in Gastroenterology, 10(2), 243-251. https://doi.org/10.1177/1756283X16681701
Fass R, Frazier R. The Role of Dexlansoprazole Modified-release in the Management of Gastroesophageal Reflux Disease. Therap Adv Gastroenterol. 2017;10(2):243-251. PubMed PMID: 28203282.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. AU - Fass,Ronnie, AU - Frazier,Rosita, Y1 - 2017/01/05/ PY - 2016/07/28/received PY - 2016/10/20/accepted PY - 2017/2/17/entrez PY - 2017/2/17/pubmed PY - 2017/2/17/medline KW - dexlansoprazole modified-release KW - gastroesophageal reflux disease KW - proton-pump inhibitor SP - 243 EP - 251 JF - Therapeutic advances in gastroenterology JO - Therap Adv Gastroenterol VL - 10 IS - 2 N2 - Dexlansoprazole modified-release (MR) is the R-enantiomer of lansoprazole and is currently the only proton-pump inhibitor (PPI) with a novel dual delayed release (DDR) formulation. Overall, dexlansoprazole MR demonstrates a similar safety and side-effect profile as lansoprazole. Dexlansoprazole MR has been shown to be highly efficacious in healing erosive esophagitis, maintaining healed esophageal mucosa in patients with erosive esophagitis and controlling symptoms of patients with nonerosive reflux disease (NERD). Recent studies have also demonstrated that dexlansoprazole MR is highly effective in improving nocturnal heartburn, gastroesophageal reflux disease (GERD) related sleep disturbances and bothersome regurgitation. Dexlansoprazole MR is well tolerated and can be taken without regard to food. SN - 1756-283X UR - https://www.unboundmedicine.com/medline/citation/28203282/The_role_of_dexlansoprazole_modified_release_in_the_management_of_gastroesophageal_reflux_disease_ L2 - http://journals.sagepub.com/doi/full/10.1177/1756283X16681701?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.